Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Döhner, Elihu Estey, David Grimwade, Sergio Amadori, Frederick R. Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L. Ebert, Pierre Fenaux, Richard A. Larson, Ross L. Levine, Francesco Lo-Coco, Tomoki Naoe, Dietger Niederwieser, Gert J. Ossenkoppele, Miguel Sanz, Jorge Sierra, Martin S. Tallman, Hwei-Fang Tien, Andrew H. Wei, Bob Löwenberg and Clara D. Bloomfield


The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults published in 2010 has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease, as well as in the development of novel anti-leukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on minimal residual disease status, and criteria for progressive disease.

  • Submitted August 12, 2016.
  • Accepted November 15, 2016.